CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
CLINUVEL’s CYACÊLLE CLINUVEL today launched CYACÊLLE, a next generation of polychromatic solar care. CYACÊLLE is…
CLINUVEL’s CYACÊLLE CLINUVEL today launched CYACÊLLE, a next generation of polychromatic solar care. CYACÊLLE is…
JEFFERSONVILLE, Ohio, Mar 1, 2023 – (JCN Newswire) – Honda and LG Energy Solution (LGES;…
NEW YORK–(BUSINESS WIRE)–#A–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces…
DALLAS–(BUSINESS WIRE)–On February 28, 2023, Holly Energy Partners, L.P. (NYSE: HEP) (the “Partnership”) filed with…
Stockholders also voted in favor of the Yorkville share issuance proposal to issue shares in…
Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13 Company Remains On-Track…
Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13 Company Remains On-Track…
THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will…
THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will…
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time…
Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time…
NEWS RELEASEFEBRUARY 28, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM –…
NEWS RELEASEFEBRUARY 28, 2023, 4:30 pm ET/ 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM –…
EDMONTON, ALBERTA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, Feb. 28, 2023 (GLOBE NEWSWIRE) — Atlas Global…
EDMONTON, ALBERTA, CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, Feb. 28, 2023 (GLOBE NEWSWIRE) — Atlas Global…
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022….
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce…
Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022….